Let’s shape the future of med-tech together
Mr Rajko Babovic, Chief Executive Officer SOMAPHARM AG Mr Babovic is the new wind at SOMA+PHARM After creating the new business and development plan for
Mr Rajko Babovic, Chief Executive Officer SOMAPHARM AG Mr Babovic is the new wind at SOMA+PHARM After creating the new business and development plan for
Mr Manfred Weisser, Research & Development Director SOMA+PHARM AG Mr Weisser is the legacy guarantee at SOMA+PHARM. After years of business activity in healthcare and
Dear Sir or Madam, in the last six months, there have been many positive business developments. We have repositioned ourselves and will inform you shortly.
On November 25, 2019, our very successful first event for investors and interested parties took place. The response of the attendees, from private persons to
With the successful proof of principle tests at the University Hospital in Tübingen, we have taken the next step towards licensing BioTempero and are thus
The management of Somapharm AG is proud and pleased about the completion and dispatch of the new share certificates for our shareholders. Since the parliamentary
The fast and precise screening method for early detection of heart disease and prevention of a surprising heart attack. Complementing ALiSE, we are launching Cardisio,
The management of Somapharm AG is very pleased to have been granted exclusive distribution rights in Europe, including Switzerland, for a new portable and miniaturized
In cooperation with the company FISO Technologies Inc. from Canada, and supported by Innoswiss, a new sensor for intensive care measurement purposes is currently being
The documents for the clinical tests were submitted to the Ethics Committee of the University Hospital in Tübingen towards the end of March. The approval
Somapharm AG was able to engage one of the world’s most renowned neurosurgeons, Prof. Dr. med. Aminadav Mendelowitsch, in persona as consultant. Prof. Mendelowitsch advises